Voltar
Revisão Revisado por pares
BIBTEX RIS

HCV NS5A Inhibitors in Development

2012; Elsevier BV; Volume: 17; Issue: 1 Linguagem: Inglês

10.1016/j.cld.2012.09.006

ISSN

1557-8224

Autores

Anna Suk‐Fong Lok,

Tópico(s)

Monoclonal and Polyclonal Antibodies Research

Resumo

NS5A protein plays a key role in hepatitis C virus (HCV) replication. Daclatasvir (DCV, BMS-790052) is a first-in-class inhibitor of the HCV NS5A replication complex with potent antiviral activity but a low barrier to resistance. DCV as triple therapy in combination with pegylated interferon and ribavirin resulted in a high rate of early virologic response in treatment-naïve patients with genotype 1 infection; as quadruple therapy in combination with asunaprevir (BMS-650032, NS3 protease inhibitor), pegylated interferon, and ribavirin, it resulted in a high rate of sustained virologic response in genotype 1 prior null responders.

Referência(s)